洽洽食品(002557.SZ):華能信託增持399.7萬張洽洽轉債
格隆匯11月18日丨洽洽食品(002557.SZ)公佈,經中國證監會《關於核准洽洽食品股份有限公司公開發行可轉換公司債券的批覆》(證監許可[2020]2297號)核准,公司於2020年10月20日公開發行1340萬張可轉換公司債券(債券簡稱:洽洽轉債,債券代碼:128135),每張面值100元,發行總額13.40億元。
2020年11月18日,公司接到華能貴誠信託有限公司(代表“華能信託·泰誠匯瀛集合資金信託計劃”,下稱“華能信託”)的通知,華能信託於2020年11月18日,通過深交所交易系統採取大宗交易的方式購買洽洽轉債合計399.6995萬張,佔洽洽轉債發行總量的29.83%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.